Literature DB >> 23716995

Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes.

Wen-Shan Lv1, Rui-Xia Sun, Yan-Yan Gao, Jun-Ping Wen, Rong-Fang Pan, Li Li, Jing Wang, Yu-Xin Xian, Cai-Xia Cao, Ming Zheng.   

Abstract

AIM: To evaluate the correlation between nonalcoholic fatty liver disease (NAFLD) and microvascular complications in type 2 diabetes mellitus (T2DM).
METHODS: Data were obtained from 1217 inpatients with T2DM (757 females, 460 males; aged 63.39 ± 12.28 years). NAFLD was diagnosed by hepatic ultrasonography. Diabetic nephropathy (DN), diabetic peripheral neuropathy (DPN), and diabetic retinopathy (DR) were diagnosed according to their respective criteria. The prevalence of NAFLD and the independent correlations of clinical characteristics with NAFLD were determined by cross-tabulation and logistic regression, respectively.
RESULTS: Approximately 61% of inpatients with T2DM in Qingdao, China had NAFLD, which decreased significantly with increase in age and prolonged course of diabetes. The prevalence of NAFLD in patients presenting with DN, DPN and DR was 49.4%, 57.2% and 54.9%, respectively. These rates were significantly lower than those of patients without DN, DPN and DR (65.9%, 65.6% and 66.1%, respectively, P < 0.05). Participants with NAFLD had greater body weight, waist circumference (WC), body mass index (BMI), fasting blood glucose (FBG), hemoglobin A1c, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, blood pressure, as well as triglyceride (TG) levels and lower high-density lipoprotein (HDL) concentration than those without NAFLD (P < 0.05). NAFLD was positively correlated with BMI, WC, TG, FBG, diastolic blood pressure, and systolic blood pressure but negatively correlated with the duration of diabetes, DR, DPN, DN, and HDL.
CONCLUSION: Despite the benign nature of NAFLD, efforts should be directed toward early diagnosis, intensive blood glucose and blood pressure control, and effective dyslipidemia correction.

Entities:  

Keywords:  Diabetic nephropathy; Diabetic neuropathy; Diabetic retinopathy; Nonalcoholic fatty liver disease; Type 2 diabetes mellitus

Mesh:

Year:  2013        PMID: 23716995      PMCID: PMC3662955          DOI: 10.3748/wjg.v19.i20.3134

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  [Epidemiological survey of prevalence of fatty liver and its risk factors in a general adult population of Shanghai].

Authors:  Jian Gao Fang; Jun Zhu; Xin Jian Li; Rui Li; Fei Dai; Xiao Min Song; Lan Chen; Feng Li; Shi Yao Chen
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2005-02

2.  Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.

Authors:  Leon A Adams; Scott Harmsen; Jennifer L St Sauver; Phunchai Charatcharoenwitthaya; Felicity B Enders; Terry Therneau; Paul Angulo
Journal:  Am J Gastroenterol       Date:  2010-02-09       Impact factor: 10.864

3.  [Prevalence and risk factors for diabetic retinopathy in type 2 diabetes patients in Jewish and Bedouin populations in southern Israel].

Authors:  Alexander Chorny; Tova Lifshits; Assaf Kratz; Jaime Levy; Daniel Golfarb; Alexander Zlotnik; Boris Knyazer
Journal:  Harefuah       Date:  2011-12

4.  High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease.

Authors:  Hongyun Lu; Longyi Zeng; Biao Liang; Xiaochun Shu; Danhong Xie
Journal:  Arch Med Res       Date:  2009-09-25       Impact factor: 2.235

5.  Hepatic steatosis in overweight/obese females: new screening method for those at risk.

Authors:  Giovanni Tarantino; Genoveffa Pizza; Annamaria Colao; Fabrizio Pasanisi; Paolo Conca; Patrizia Colicchio; Carmine Finelli; Franco Contaldo; Carolina Di Somma; Silvia Savastano
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

6.  Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes.

Authors:  Mariana Lazo; Steven F Solga; Alena Horska; Susanne Bonekamp; Anna Mae Diehl; Frederick L Brancati; Lynne E Wagenknecht; F Xavier Pi-Sunyer; Steven E Kahn; Jeanne M Clark
Journal:  Diabetes Care       Date:  2010-07-27       Impact factor: 19.112

Review 7.  [Non-alcoholic fatty liver disease--new view].

Authors:  Joanna Raszeja-Wyszomirska; Małgorzata Lawniczak; Wojciech Marlicz; Joanna Miezyńska-Kurtycz; Piotr Milkiewicz
Journal:  Pol Merkur Lekarski       Date:  2008-06

8.  [Study on prevalence and risk factors of fatty liver of patients with type 2 diabetes].

Authors:  Jian Zhou; Wei-Ping Jia; Yu-Qian Bao; Xiao-Jing Ma; Wei Lu; Ming Yu; Jie-Min Pan; Cheng Hu; Kun-San Xiang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2007-08-28

9.  Diabetic neuropathy is closely associated with arterial stiffening and thickness in Type 2 diabetes.

Authors:  H Yokoyama; Y Yokota; J Tada; S Kanno
Journal:  Diabet Med       Date:  2007-10-17       Impact factor: 4.359

10.  Concomitant macro and microvascular complications in diabetic nephropathy.

Authors:  Jamal S Alwakeel; Abdulkareem Al-Suwaida; Arthur C Isnani; Ali Al-Harbi; Awatif Alam
Journal:  Saudi J Kidney Dis Transpl       Date:  2009-05
View more
  24 in total

Review 1.  Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Claudia R L Cardoso; Gil F Salles
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 2.  Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.

Authors:  Qing Pang; Jing-Yao Zhang; Si-Dong Song; Kai Qu; Xin-Sen Xu; Su-Shun Liu; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 3.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

4.  Prevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus.

Authors:  Zahra Heidari; Atiyeh Gharebaghi
Journal:  J Clin Diagn Res       Date:  2017-05-01

5.  Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial.

Authors:  Keith G McCormick; Eleonora Scorletti; Lokpal Bhatia; Philip C Calder; Michael J Griffin; Geraldine F Clough; Christopher D Byrne
Journal:  Diabetologia       Date:  2015-05-29       Impact factor: 10.122

6.  High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.

Authors:  Paola Portillo-Sanchez; Fernando Bril; Maryann Maximos; Romina Lomonaco; Diane Biernacki; Beverly Orsak; Sreevidya Subbarayan; Amy Webb; Joan Hecht; Kenneth Cusi
Journal:  J Clin Endocrinol Metab       Date:  2015-04-17       Impact factor: 5.958

7.  Prevalence of nonalcoholic fatty liver disease and its association with age in patients with type 2 diabetes mellitus.

Authors:  Ryosuke Yamane; Kentaro Yoshioka; Kazuhiko Hayashi; Yuko Shimizu; Yuki Ito; Komei Matsushita; Michiyo Yoshizaki; Go Kajikawa; Taro Mizutani; Atsuko Watarai; Kosuke Tachi; Hidemi Goto
Journal:  World J Hepatol       Date:  2022-06-27

Review 8.  The Potential Role of Fatty Acids in Treating Diabetic Neuropathy.

Authors:  Mark A Yorek
Journal:  Curr Diab Rep       Date:  2018-08-25       Impact factor: 4.810

Review 9.  Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?

Authors:  Mohamed H Ahmed; Nazik Elmalaika Os Husain; Ahmed O Almobarak
Journal:  J Family Med Prim Care       Date:  2015 Jan-Mar

Review 10.  Comorbidities and Metabolic Derangement of NAFLD.

Authors:  Ki Bae Bang; Yong Kyun Cho
Journal:  J Lifestyle Med       Date:  2015-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.